Genetic testing company 23andMe has filed for bankruptcy after a significant decline from a $6 billion valuation to $50 million, as reported by Tech News Weekly featuring a discussion with Geoffrey Fowler of the Washington Post. This downfall followed unsuccessful attempts to generate sustainable revenue through pharmaceutical partnerships and other ventures. A major cybersecurity breach severely damaged public trust and consumer confidence. Consequently, customers are urged to protect their privacy by utilizing data deletion options provided by privacy laws like California's CCPA. The situation underscores the critical importance of data protection in the realm of personal genetic information.
